BR112023025264A2 - Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida - Google Patents
Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamidaInfo
- Publication number
- BR112023025264A2 BR112023025264A2 BR112023025264A BR112023025264A BR112023025264A2 BR 112023025264 A2 BR112023025264 A2 BR 112023025264A2 BR 112023025264 A BR112023025264 A BR 112023025264A BR 112023025264 A BR112023025264 A BR 112023025264A BR 112023025264 A2 BR112023025264 A2 BR 112023025264A2
- Authority
- BR
- Brazil
- Prior art keywords
- difluoro
- carboxamide
- trifluoromethyl
- carbonyl
- pyridine
- Prior art date
Links
- XSQUJFKRXZMOKA-PAFIKIDNSA-N FC=1C(=C(C=CC=1F)[C@H]1[C@@H](O[C@]([C@H]1C)(C(F)(F)F)C)C(=O)NC1=CC(=NC=C1)C(=O)N)OC Chemical compound FC=1C(=C(C=CC=1F)[C@H]1[C@@H](O[C@]([C@H]1C)(C(F)(F)F)C)C(=O)NC1=CC(=NC=C1)C(=O)N)OC XSQUJFKRXZMOKA-PAFIKIDNSA-N 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida. a presente invenção refere-se a uma dispersão sólida de (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino]piridina-2-carboxamida (composto 1), definido como aqui descrito, ou um sal farmaceuticamente aceitável do mesmo e um comprimido contendo a dispersão sólida para o tratamento da dor. também aqui divulgado é composto 1 ou um sal farmaceuticamente aceitável do mesmo para uso em um método de tratamento da dor.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163196933P | 2021-06-04 | 2021-06-04 | |
US202163196937P | 2021-06-04 | 2021-06-04 | |
US202163285201P | 2021-12-02 | 2021-12-02 | |
US202163285197P | 2021-12-02 | 2021-12-02 | |
PCT/US2022/032253 WO2022256708A1 (en) | 2021-06-04 | 2022-06-03 | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023025264A2 true BR112023025264A2 (pt) | 2024-02-20 |
Family
ID=82492526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023025264A BR112023025264A2 (pt) | 2021-06-04 | 2022-06-03 | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4346818A1 (pt) |
JP (1) | JP2024520649A (pt) |
KR (1) | KR20240031299A (pt) |
AU (1) | AU2022284952A1 (pt) |
BR (1) | BR112023025264A2 (pt) |
CA (1) | CA3222197A1 (pt) |
IL (1) | IL308954A (pt) |
TW (1) | TW202317108A (pt) |
WO (1) | WO2022256708A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024146632A1 (zh) * | 2023-01-06 | 2024-07-11 | 西藏海思科制药有限公司 | 一种四氢噻吩衍生物及其在医药上的应用 |
CN117838648B (zh) * | 2024-03-05 | 2024-05-28 | 瑞阳制药股份有限公司 | Suzetrigine片剂及其制备方法 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
DE60123797T2 (de) | 2000-07-10 | 2007-10-18 | Vertex Pharmaceuticals (San Diego) Llc, San Diego | Ionenkanal-testverfahren |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6492618B1 (en) | 2000-11-02 | 2002-12-10 | Tri Tool Inc. | Automatic weld head alignment and guidance system and method |
WO2006011050A2 (en) | 2004-07-23 | 2006-02-02 | Pfizer Limited | Pyridine derivatives |
WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
MX2011006904A (es) | 2008-12-26 | 2011-07-20 | Dainippon Sumitomo Pharma Co | Compuesto heterociclico biciclico novedoso. |
US9174999B2 (en) | 2009-05-07 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
CA2771472A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
AU2012212196B2 (en) | 2011-02-02 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
CA2827311A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
US20140187533A1 (en) | 2011-03-03 | 2014-07-03 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
CA2829803A1 (en) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
AU2012328034B2 (en) | 2011-10-26 | 2015-04-23 | Pfizer Limited | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators |
EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
CN104136442B (zh) | 2012-01-16 | 2016-12-21 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 |
WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
CN104968647B (zh) | 2013-01-31 | 2018-01-26 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的酰胺 |
EP2953931B1 (en) | 2013-01-31 | 2017-03-01 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
AU2014212426B8 (en) | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
CA2944549A1 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxin useful for the treatment of pain |
AR103833A1 (es) | 2015-03-02 | 2017-06-07 | Amgen Inc | Compuestos bicíclicos de sulfonamida cetona |
WO2017059385A1 (en) | 2015-09-30 | 2017-04-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
CN110914276A (zh) | 2017-03-29 | 2020-03-24 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
KR20200012833A (ko) | 2017-03-29 | 2020-02-05 | 사이트원 테라퓨틱스, 인코포레이티드 | 통증 치료용 11,13-개질된 색시톡신 |
CN110740993B (zh) | 2017-05-16 | 2023-09-01 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的氘代吡啶酮酰胺及其前药 |
MA49566A (fr) | 2017-07-11 | 2020-05-20 | Vertex Pharma | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
KR20200040269A (ko) * | 2017-08-11 | 2020-04-17 | 메르크 파텐트 게엠베하 | 3-플루오로-4-[7-메톡시-3-메틸-8-(1-메틸-1H-피라졸-4-일)-2-옥소-2,3-디하이드로-이미다조[4,5-c]퀴놀린-1-일]-벤조니트릴을 포함하는 약학 제제 |
EP3820866A4 (en) | 2018-07-09 | 2022-04-06 | Lieber Institute, Inc. | PYRIDINE CARBOXAMIDE COMPOUNDS TO INHIBIT NAV1.8 |
CN112689629B (zh) | 2018-07-09 | 2024-04-23 | 利伯研究所公司 | 用于抑制Nav1.8的哒嗪化合物 |
WO2020072835A1 (en) | 2018-10-03 | 2020-04-09 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
CN113272293B (zh) | 2018-11-02 | 2024-06-14 | 默沙东有限责任公司 | 作为nav1.8抑制剂的2-胺基-n-杂芳基-烟酰胺 |
US20220119363A1 (en) | 2018-11-02 | 2022-04-21 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
BR112021012909A2 (pt) | 2019-01-04 | 2021-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo |
WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
CN112996774B (zh) | 2019-01-25 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
US20230103791A1 (en) | 2019-06-27 | 2023-04-06 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
CN112300069A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
CN112300051A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
CN112390745B (zh) | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2021032074A1 (zh) | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
CN112441969A (zh) | 2019-08-30 | 2021-03-05 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
WO2021047622A1 (zh) | 2019-09-12 | 2021-03-18 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物及其制备方法和用途 |
JOP20220130A1 (ar) | 2019-12-06 | 2023-01-30 | Vertex Pharma | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم |
CN111217776A (zh) | 2020-01-19 | 2020-06-02 | 中国人民解放军军事科学院军事医学研究院 | 含苯并杂环结构的酰胺衍生物、组合物和应用 |
JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
JP2021195368A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
WO2021252822A1 (en) | 2020-06-10 | 2021-12-16 | Amgen Inc. | Heteroalkyl dihydroquinoline sulfonamide compounds |
EP4167994A4 (en) | 2020-06-17 | 2024-07-24 | Merck Sharp & Dohme Llc | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS |
CA3180372A1 (en) | 2020-06-17 | 2021-12-23 | Ashok Arasappan | 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors |
CR20220642A (es) | 2020-06-17 | 2023-02-15 | Merck Sharp & Dohme Llc | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 |
MX2023001741A (es) | 2020-08-14 | 2023-04-25 | Siteone Therapeutics Inc | Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor. |
TW202214259A (zh) | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性NaV抑制劑的前藥及其晶型 |
TW202220962A (zh) | 2020-08-19 | 2022-06-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 選擇性NaV抑制劑的結晶形式及其製備方法 |
CN111808019B (zh) | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
CN112225695B (zh) | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
CN112457294B (zh) | 2021-01-27 | 2021-06-04 | 上海济煜医药科技有限公司 | 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途 |
-
2022
- 2022-06-03 EP EP22741050.3A patent/EP4346818A1/en active Pending
- 2022-06-03 IL IL308954A patent/IL308954A/en unknown
- 2022-06-03 CA CA3222197A patent/CA3222197A1/en active Pending
- 2022-06-03 AU AU2022284952A patent/AU2022284952A1/en active Pending
- 2022-06-03 BR BR112023025264A patent/BR112023025264A2/pt unknown
- 2022-06-03 WO PCT/US2022/032253 patent/WO2022256708A1/en active Application Filing
- 2022-06-03 KR KR1020247000227A patent/KR20240031299A/ko unknown
- 2022-06-03 JP JP2023574381A patent/JP2024520649A/ja active Pending
- 2022-06-06 TW TW111120909A patent/TW202317108A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL308954A (en) | 2024-01-01 |
TW202317108A (zh) | 2023-05-01 |
KR20240031299A (ko) | 2024-03-07 |
AU2022284952A1 (en) | 2023-12-14 |
JP2024520649A (ja) | 2024-05-24 |
WO2022256708A1 (en) | 2022-12-08 |
EP4346818A1 (en) | 2024-04-10 |
CA3222197A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023025264A2 (pt) | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida | |
RU2367471C2 (ru) | Способы лечения интерлейкин-6-зависимых заболеваний | |
Colla et al. | Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice | |
DE69634609D1 (de) | Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten | |
BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BR112012029959A2 (pt) | compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo | |
BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
BRPI0708640A8 (pt) | composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca | |
Podkowa et al. | Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495 | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
Roh et al. | Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model | |
Sałat et al. | Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain | |
BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
BR0315593A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
BR112022015363A2 (pt) | Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo | |
BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
Shen et al. | The dopamine D1–D2 receptor heteromer exerts a tonic inhibitory effect on the expression of amphetamine-induced locomotor sensitization | |
BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
Rénéric et al. | In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed | |
BR112019008359A2 (pt) | método para tratamento da doença de alzheimer, e, composição farmacêutica. | |
Caputi et al. | Evidence of a PPARγ-mediated mechanism in the ability of Withania somnifera to attenuate tolerance to the antinociceptive effects of morphine | |
BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
Wu et al. | Attenuation of toluene-induced brain stimulation reward enhancement and behavioral disturbances by N-acetylcysteine in mice |